cryobio

Additional Agreement to Use Donor CB 953-B

We, _____ (Recipient), and _____ (Partner, if applicable), specifically request and accept frozen semen from Cryobio donor CB 953-B. We understand that this Additional Agreement is an additional part of the Sperm Use Agreement specific to donor CB 953-B. We reviewed the genetic test results on this sperm donor, and we understand that donor CB 953-B has been found to be a carrier of the following recessive genetic condition:

Glycogen Storage Disease, Type V.

Why carrier status is important: Carriers of genetic diseases have changes, called pathogenic variants or mutations, in a specific (or multiple) gene(s). Most of the genetic diseases that the Cryobio donors are tested for are inherited in an autosomal recessive pattern. Typically, we all have two copies of every gene---one from the egg source and one from the sperm source. Autosomal recessive diseases require a mutation in both copies of the same gene in order for it to cause disease. Therefore, individuals who carry just one mutation in a gene that causes recessive disease are 'carriers' of that specific disease. Carriers of most of the genetic diseases Cryobio donors are tested for do not show symptoms of the disease, i.e. they are asymptomatic. Some diseases tend to occur more in certain ethnicities, and some tend to occur evenly in all ethnicities. Most individuals are carriers for at least one if not multiple recessive genetic diseases.

Carrier status is important because if both the egg source and the sperm source are carriers for pathogenic variants or mutations in the same gene, then there is a 1 in 4 chance of the resulting child having that specific disease; a 2 in 4 chance of the resulting child being a carrier for that specific disease; and a 1 in 4 chance of the resulting child being neither a carrier nor having that specific disease. Some of the diseases Cryobio donors are tested for have genotype-phenotype correlation, meaning that specific genetic pathogenic variations (the genotype) in a specific gene can be predictive of the type of specific disease that may present in the individual (the phenotype), but not all do.

Glycogen storage disease, type V (PYGM gene):
Glycogen storage disease, type V (GSD5) is an autosomal recessive metabolic disease caused by pathogenic variants in the gene *PYGM*. GSD5 may affect people of any ethnicity, but it is more common among Sephardic Jewish individuals from Iran, Iraq, and Syria. GSD5 primarily affects the muscles, and characteristic symptoms include exercise intolerance, muscle pain, muscle weakness, and in severe cases can cause rhabdomyolysis (break down of the muscle tissue). However, most individuals are able to tolerate mild exercise and stay physically fit. The severity of the exercise intolerance and symptoms is variable. Onset is typically in the first decade of life, although some individuals may present in their 20s or older. Most individuals are able to adjust their daily life based on the severity of their symptoms, and life expectancy is not affected. It is not currently possible to predict how severe the disease will be based on the inherited variants.

Carrier status frequency:
Carrier status frequency is the chance of an individual being a carrier for a genetic condition based on their ethnicity alone prior to any genetic screening. If an individual tests negative as a carrier for a condition or conditions, then the chance of being a carrier is significantly decreased. This remaining risk is known as residual risk, meaning what is the risk of being a carrier even after negative genetic testing. Residual risk data is available directly through sema4's website, sema4.com, or can be requested from Cryobio.

Glycogen storage disease, type V (PYGM gene) carrier status frequency in different ethnicities, from Sema4's website:

African	1 in 220
Ashkenazi Jewish	1 in 120
East Asian	1 in 368
Finnish	1 in 518
European (Non-Finnish)	1 in 116
Native American	1 in 147
South Asian	1 in 366
Worldwide	1 in 158

Recommendation: Both Sema4 and Cryobio recommend that the recipient, or egg source if different than recipient, be tested for glycogen storage disease, type V carrier status and consider genetic counseling. Please refer to Sema4's website, sema4.com, for more information and contact Cryobio with any questions or to arrange genetic counseling. Because the donor was tested by Sema4, Cryobio recommends that the recipient or egg source should be tested by Sema4 as well. We also strongly recommend that you discuss the donor's genetic carrier status results with your health care provider. Finally, we recommend that any future child be notified of this donor's carrier status once they are of reproductive age, as even if they do not have a recessive disease, they could be a carrier and their carrier status could be important to identify risks related to their own reproductive future.

Cryobio has advised us of the following:	**Please initial to show your understanding and agreement:**
The donor we have chosen has positive results from genetic testing. These results indicate that the donor is a carrier for glycogen storage disease, type V.	**Initials:** _____ **Initials:** _____
This genetic condition is inherited as a recessive trait. This means that if both the egg source and the sperm source are carriers for the same condition, there is a significantly higher chance of the resulting child having that genetic condition.	**Initials:** _____ **Initials:** _____
By the donor testing positive for carrier status for glycogen storage disease, type V, the risk to a resulting child would now be higher than that of the general population.	**Initials:** _____ **Initials:** _____
Both the risk of being a carrier and the sensitivity of the genetic testing can vary depending on an individual's ethnicity. When an individual tests negative for carrier status, it ***does not completely eliminate*** their chance of being a carrier for that disease. Instead, their remaining (residual) risk of being a carrier is determined by their ethnic background. While a negative result decreases the likelihood that an individual is a carrier, how much that risk is reduced can vary significantly. For more detailed information regarding the sensitivity of testing and remaining risk after negative screening, please see Sema4's website.	**Initials:** _____ **Initials:** _____

Genetic testing looking at a large panel of genes, including the genes/conditions that the donor has tested positive for, is available and could be done.	**Initials: _____ Initials: _____**
Genetic testing is ***strongly recommended*** for me (or the egg source, if different) to see if I am a carrier for glycogen storage disease, type V.	**Initials: _____ Initials: _____**
A negative genetic test result in me (or the egg source, if different) significantly reduces the likelihood that the resulting child could be affected with these conditions. However, we fully understand that the risk cannot be completely eliminated.	**Initials: _____ Initials: _____**
While genetic testing can lower the likelihood for certain genetic diseases, no amount of genetic testing can guarantee that a child will be healthy or free of genetic disease.	**Initials: _____ Initials: _____**
Genetic counseling is available to us, either through Cryobio or Sema4, if we have additional questions regarding these test results and potential risks.	**Initials: _____ Initials: _____**
Both the donor's carrier status and whether the donor is acceptable for my use should be discussed with my health care provider.	**Initials: _____ Initials: _____**

We have read the above material and assume the risk of using donor sperm from a donor who has been found to be a carrier of a genetic disorder. We are making the choice to use donor sperm from donor CB 953-B willingly and agree to release any legal claims, including negligence, that may arise from or are related to insemination or assisted reproduction using donor sperm from donor CB 953-B.

We have read and had the chance to ask questions, and we understand and agree to the terms of this Additional Agreement to use donor CB 953-B.

_____
Recipient

_____
Date

_____
Partner, if applicable

_____
Date

William C. Baird, PhD

_____
Cryobio

04-26-2022

_____
Date